• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Ariad Pharmaceuticals

Ariad Pharmaceuticals

  1. All
  2. 3rd Party
  1. ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial

    ARIAD Announces Long-Term Safety and Efficacy Data of Ponatinib from Phase 2 Pace Clinical Trial

  2. Gastrointestinal Stromal Tumor (GIST) Report 2016 - Pipeline Review of 23 Pharma Companies & Drug Profiles - Research and Markets

    Gastrointestinal Stromal Tumor (GIST) Report 2016 - Pipeline Review of 23 Pharma Companies & Drug Profiles - Research and Markets

  3. ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients

    ARIAD Presents Long-Term Phase 1/2 Trial Follow up on Investigational Drug Brigatinib with Median Time on Treatment of 17 Months in ALK+ NSCLC Patients

  4. ARIAD to Present at the Jefferies 2016 Global Healthcare Conference

    ARIAD to Present at the Jefferies 2016 Global Healthcare Conference

  5. ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary ...

    ARIAD Presents Data from Mutational Profiling in Crizotinib-Resistant Patients Treated with Investigational Medicine Brigatinib Showing Similar Response Rates in Patients with and without Secondary ALK Mutations

  6. The Top-Performing Funds in 2011's Toughest Category

    These two small-value funds have followed different paths to success in a difficult year for the peer group.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.